Doctorate of Clinical Hematology
Dr. Rizwan Shaikh
MBBS, MD, DrNB
Dr Mohd Rizwan Shaikh is a Hematologist, Hemato-oncologist and Bone Marrow Transplant Physician.
Dr Shaikh is certified in Internal Medicine and Clinical Hematology. He has been trained in Internal Medicine at the prestigious Seth GS Medical College, Mumbai. He holds a Doctorate in Clinical Hematology from Rajiv Gandhi Cancer Institute and Research Centre, Delhi.
He has been instrumental in re-structuring and expanding the Department of Hemato-oncology and BMT at Max Super Specialty Hospital, Saket, Delhi.
He has been deeply involved in the establishing of treatment protocols for relapsed and refractory cases of hematological malignancies at the Seth GS Medical College and KEM Hospital, Mumbai while he was associated with it as an Assistant professor. He is also closely associated with the development of bone marrow transplant at Seth GS Medical College and KEM Hospital, Mumbai.
Having worked at corporate, trust based, and government run organizations. He felt a sense of unmet need different systems. He is currently working to make quality blood cancer care accessible and affordable to all patients who need it.
BloodCancerHelpline.com is a step in that direction.
Expertise:
- One good thing about blood cancer is that it is curable.
- Dr Shaikh has numerous publications on individualized leukemia, lymphoma and myeloma care on novel combinations of targeted and immunotherapies which unleash the potential of these drugs to beat blood cancer at all stages of presentations, be it frontline, relapsed or refractory.
Education and Training:
- MBBS at Lokmanya Tilak Municipal Medical College, Mumbai
- MD (Internal Medicine) at Seth GS Medical College and KEM Hospital, Mumbai
- DrNB (Clinical Hematology) at Rajiv Gandhi Cancer Institute and Research Centre, Delhi
Clinical Experience:
- Dr Rizwan has a rich clinical experience having trained at prestigious institutes.
- He trained in the Department of Medicine at KEM Hospital that sees more than 1 lakh inpatients every year and Department of Hematology at Rajiv Gandhi Cancer Institute and Research Centre, Delhi which does more than 100 bone marrow transplants per year. Dr Rizwan brings with him not only a razor-sharp clinical acumen but also a profound sense of empathy.
- His patient benefit from his vast clinical experience which helps them conquer cancer.
Research & Publications:
- Mirgh S, Sharma A, Shaikh MRMA, Kadian K, Agrawal N, Khushoo V, Mehta P, Ahmed R, Bhurani D. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021 Jun 15;11(3):290-302. PMID: 34322294; PMCID: PMC8303019.
- Shaikh MRMA, Mehta P, Mirgh S. Individualized AML Induction with Venetoclax Based Therapy in Unfit Treatment Naïve Patients Aged ≤ 60 Years: A Real World Perspective from India. Blood 2021, 4417-4417, 138(Supplement 1)
- Shaikh MR, Folbs B, Agrawal N. Acute pancreatitis in Thalassemia post allogeneic stem cell transplant with Cyclosporine-A as a possible etiology: a report of two cases. IJ Clin Img and med Rew. 2021; 1(1): 1008.
- Kapoor J, Shaikh MR, Agrawal N. An ‘Uncommon early lineage switch’ in an MLL rearranged adult B-lineage Acute Lymphoblastic Leukemia to Mixed-phenotypic acute leukemia (B/Myeloid). IJ Clin Img and med Rew. 2021;1(1): 1003
- Shaikh MR, Singh B, Halder R, Singh R, Shaikh MR, Agarwal N, Bansal N, Ahmed R, Mirgh SP, Bhurani D. FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines". Leuk Res. 2023 Sep;132:107346. doi: 10.1016/j.leukres.2023.107346. Epub 2023 Jun 28. PMID: 37467566.
- Mohd Rizwan Mohamad Anwar Shaikh, Bhumika Singh , Reema Singh, Rohan Halder, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani. A Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India. Blood (2023) 142 (Supplement 1): 5842.
- Rainchwar S, Naim F, Panda T, Shaikh M, Chand R, Soni M, Halder R, Dinesh B, Agrawal, N, Ahmed R. (2024). CT-678 Haploidentical HSCT With Fludarabine, Melphalan 75 mg/m2 and 400 cGy TBI: A Tolerable Conditioning Regimen With Low Toxicity and Good Anti-Leukemic Activity. Clinical Lymphoma Myeloma and Leukemia. 24. S613-S614. 10.1016/S2152-2650(24)01794-4.
- Soni M, Rainchwar S, Shaikh M, Singh R, Sheth V, Panda T, Halder R, Palatty R, Agrawal N,Senapati J, Bhurani D. (2024). AML-696 Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario. Clinical Lymphoma Myeloma and Leukemia. 24. S331. 10.1016/S2152-2650(24)01235-7.
- Rashmi ahmed Chand, Faran Naim, Rashmi Chand II, Huma Quasimi, Rahul Sharma, Rajan Kapoor, Rajiv Kumar, Lorie Gandhi, Devyani Surange, Mohd Rizwan Mohamad Anwar Shaikh. Sequential Pembrolizumab Followed By AVD in Advanced Hodgkin Lymphoma: A Retrospective Study from North India Blood (2024) 144 (Supplement 1): 6375